Market Place
Sourcing Support
Aptevo Reports Q3 2024 Financials & Business Update
07 Nov 2024 //
ACCESSWIRE
Aptevo and Alligator Present Positive ALG.APV-527 Data at SITC 2024
29 Oct 2024 //
ACCESSWIRE
Aptevo Closes $3M Offering Under Nasdaq Rules
18 Sep 2024 //
ACCESSWIRE
Aptevo And Alligator Announce ALG.APV-527 Trial Data
16 Sep 2024 //
ACCESSWIRE
Aptevo Therapeutics Announces $3.0 Million Offering
16 Sep 2024 //
ACCESSWIRE
Aptevo And Alligator Present ALG.APV-527 Data For Solid Tumors At ESMO
13 Sep 2024 //
ACCESSWIRE
Aptevo Therapeutics Reports Q2 2024 Results And Business Update
08 Aug 2024 //
ACCESSWIRE
Aptevo Therapeutics Announces Closing of $2.75 Million Offering
01 Jul 2024 //
ACCESSWIRE
Aptevo Therapeutics Announces $2.75 Million Offering
28 Jun 2024 //
ACCESSWIRE
Aptevo Participating in the BIO International Convention
03 Jun 2024 //
ACCESSWIRE
Aptevo Presenting At Protein & Antibody Engineering Summit
14 May 2024 //
ACCESSWIRE
Aptevo Reports Q1 2024 Results, Business Update
08 May 2024 //
ACCESSWIRE
Aptevo Closes $4.6M Public Offering
15 Apr 2024 //
ACCESSWIRE
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
11 Apr 2024 //
ACCESSWIRE
Aptevo Therapeutics Provides Pipeline Update
10 Apr 2024 //
ACCESSWIRE
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
18 Mar 2024 //
PRESS RELEASE
Alligator and Aptevo Announce Positive Data of Dose Escalation Ph of ALG.APV-527
07 Mar 2024 //
ACCESSWIRE
Aptevo Reports 2023 Financial Results and Provides a Business Update
05 Mar 2024 //
ACCESSWIRE
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split
04 Mar 2024 //
ACCESSWIRE
Aptevo Reports 3Q23 Financial Results and Provides a Business Update
14 Nov 2023 //
ACCESSWIRE
Aptevo Therapeutics Reports 2Q23 Financial Results
10 Aug 2023 //
ACCESSWIRE
Aptevo Announces Closing of Previously Announced $5 Million Public Offering
04 Aug 2023 //
ACCESSWIRE
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
01 Aug 2023 //
ACCESSWIRE
Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating APVO436
18 Jul 2023 //
ACCESSWIRE
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding
30 Mar 2023 //
ACCESSWIRE
Alligator & Aptevo Announce Dosing of First Patient with ALG.APV-527 in PI Trial
13 Feb 2023 //
ACCESSWIRE
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436
12 Dec 2022 //
ACCESSWIRE
Aptevo Therapeutics Reports 3Q 2022 Financial Results and Business Highlights
10 Nov 2022 //
ACCESSWIRE
Alligator Bioscience & Aptevo Announce Publication Highlighting ALG.APV-527 s
09 Nov 2022 //
ACCESSWIRE
Aptevo Therapeutics Announces Presentation at 64th ASH Meeting
03 Nov 2022 //
ACCESSWIRE
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued
19 Sep 2022 //
ACCESSWIRE
Aptevo Therapeutics Reports Q2 2022 Rusult and Business Highlights
11 Aug 2022 //
ACCESSWIRE
Aptevo Shows Monotherapy Patient Received Transplant in APVO436 Expansion Trial
29 Mar 2022 //
PRESS RELEASE
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
24 Mar 2022 //
PRESS RELEASE
Aptevo Soars on Reports of Complete Remission in AML
23 Nov 2021 //
BIOSPACE
Aptevo Therapeutics Announces Preclinical Data for APVO603
11 Nov 2021 //
BIOSPACE
Aptevo Therapeutics Reports Second Quarter Financial Results
12 Aug 2021 //
BIOSPACE
Aptevo Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436
27 May 2021 //
ACCESSWIRE
Mexico to start late-stage clinical trial for China`s mRNA COVID-19 vaccine
12 May 2021 //
REUTERS
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
11 May 2021 //
BIOSPACE
Aptevo Therapeutics to Present at the American Association for Cancer Research
09 Apr 2021 //
BIOSPACE
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
11 Jan 2021 //
ACCESSWIRE
Aptevo Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX™
04 Dec 2020 //
BLOOMBERG
Aptevo Announces Launch Of Second Platform Technology ADAPTIR-FLEX
02 Dec 2020 //
BENZINGA
Aptevo Announces First Complete Remission in Ongoing APVO436 Ph1 Trial
03 Nov 2020 //
ACCESSWIRE
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
01 Sep 2020 //
BIOSPACE
Aptevo Secures $25 M Non-Dilutive Financing from Midcap Financial Trust
06 Aug 2020 //
ACCESSWIRE
Aptevo Therapeutics Engages Piper Sandler to Sell its RUXIENCE(R)
21 Jul 2020 //
MARKETWATCH
Aptevo to receive Seven Year Quarterly Royalty Payment Stream from Pfizer
25 Jun 2020 //
BLOOMBERG
Aptevo and Alligator Bioscience Present new Preclinical Data for ALG.APV-527
10 Jun 2020 //
PRNEWSWIRE
Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial
16 Mar 2020 //
ACCESSWIRE
